PCAF-IN-1 is a highly selective PCAF (p300/CBP-associated factor) inhibitor with potential anti-tumor, anti-inflammatory, and anti-heart disease effects. Inhibition of PCAF attenuates cardiac remodeling after myocardial infarction, reduces polarization of M1-type macrophages, and attenuates autoimmune arthritis.